Biologics. Biologics. The Centre for Process Innovation. From innovation to commercialisation

Size: px
Start display at page:

Download "Biologics. Biologics. The Centre for Process Innovation. From innovation to commercialisation"

Transcription

1 Biologics Biologics The Centre for Process Innovation From innovation to commercialisation

2 The Centre for Process Innovation From innovation to commercialisation The High Value Manufacturing Catapult is a partnership between industry and government, which is a catalyst for the future growth and success of manufacturing in the UK. Its long-term goal is to stimulate growth in the manufacturing sector and grow the sector s contribution to UK GDP to a level more commensurate with that of competitor economies. It does this by helping businesses accelerate new concepts (often started in research institutions) to commercial reality (where they can be funded through market sources). In doing so, the Catapult reduces companies risk in innovation, and it enables the UK to address market needs in key areas, making the country more competitive on the global stage. The High Value Manufacturing Catapult combines the strengths of seven UK technology and innovation centres, each focusing on major underpinning manufacturing technologies. The Catapult brings these centres together to develop cross sector manufacturing capabilities, which can span from raw materials to finished processes. It also enables innovation to cut across sectors by bringing together businesses from diverse industries and giving them access to a pool of world-class expertise, equipment and processes invested and supported by UK government. CPI is the UK s national technology and innovation centre for the process manufacturing industries. At the National Biologics Manufacturing Centre, CPI combines state of the art facilities and technical expertise to support the growth and development of the UK biologics industry and supply chain. The UK has a strong history of academic research and a rich landscape of capability and infrastructure in biologics, but in the face of increasing global competition and investment, interventions are required to anchor this high value sector in the UK. CPI collaborates with large corporates, SME s, academia and charities to enable the delivery of innovative manufacturing solutions to accelerate the growth of new and emerging biologic medicines. Through these collaborations we develop, prove and commercialise innovative new processes and technologies that enable the cost effective, safe and high quality manufacture of life changing biologic therapies. CPI is focussed on three key themes: Innovative processes and technologies New and improved analytical technologies Process development for novel products and formulations

3 Introduction CPI established the UK s National Biologics Manufacturing Centre in 2015 with funding from the Government s Department for Business Innovation and Skills. The state-of-the-art facility is equipped with advanced technologies for upstream and downstream processing, high throughput process development, comprehensive analytical characterisation and capabilities for formulation, fill and finish. The facility has over 700m 2 of flexible laboratories designed to handle BSL1 and BSL2 organisms. We can run whole bioprocess development programmes in our laboratories as well as developing GMP ready processes in a series of GMP proving clean rooms. The flexible design of the facility enables equipment expansion and reconfiguration to support specific projects. The CPI team bring significant expertise in all aspects of biopharmaceutical development and manufacture including mammalian and microbial process development, process scale-up and technology transfer, advanced bioanalytical development, new technology development and evaluation, advanced experimental design and multivariate data analysis. CPI supports the UK biopharmaceutical industry by engaging in a variety of collaborative work programmes to support process innovation and facilitate the development and adoption of new manufacturing and analytical technologies. Our capabilities and expertise in high throughput and novel process development enables partners and clients to bring their products to market more quickly and with reduced risk. We support SMEs, large companies and universities to translate early, proof of concept stage research into industry and market-ready technologies. Clients can also access our facility and expertise on a fee for service basis. The National Biologics Manufacturing Centre has been created to act as a central hub for the UK s Biologics industry, hosting key events and research projects and providing a central facility to advance innovation in the industry.

4 Services The highly experienced CPI team can help guide you from concept to finished product. We have scientists, engineers, scale up experts, process technologists and commercialisation specialists to take your project from early concepts through to robust manufacturing process packages and products. Our services can be customised to meet your needs wherever you are in the development process and supply chain. We are delighted to work side by side with our clients to help them overcome the challenges of commercialisation of their products and processes. Our extensive industry experience means we can make recommendations accordingly in an effort to produce the best possible outcome. We welcome all enquiries about our capabilities and equipment. It is our mission to help customers and partners maximise the potential of their products, accelerate speed-to-clinic and help reduce cost-of-goods. We pride ourselves on meeting our deliverables and adding considerable value to our partners and customers products and processes. We offer services in the following areas: Upstream Processing Downstream Processing Analytical Testing and Development Fill and Finish Manufacturability, Process Modelling and Simulation Process Economics and Evaluation Commercialisation and Business Support including IP Landscaping Public Private Project Funding Support Bespoke Training Packages

5 Upstream Processing We have upstream laboratory facilities equipped with state-of-the-art technologies to support the development, demonstration and scale-up of bioprocesses. The micro-matrix and ambr250 mini bioreactors allow scale-down, high-throughput evaluation and optimisation of critical process parameters. Optimised processes can be scaled-up and demonstrated at laboratory and pilot scale. blood gas analyser, ViCell automated cell counters and osmometers for in-process sample measurements. We also have -80 C freezers and liquid nitrogen cryobanks for long term storage of cell lines. Mammalian Mammalian cell culture capabilities are focused on the use of customer and partner supplied cell lines to produce and optimise the production of a wide range of biopharmaceutical products, recombinant therapeutic proteins and attenuated viruses (eg AAV). Microbial Combined Service Offering Establishment and storage of research cell banks Cell line/strain screening and evaluation Development of robust and scalable processes using QbD and DoE approaches Production and supply of pilot scale materials for downstream process development, analytical testing or other non-gmp studies Development of process models Our work is supported by a range of static and shaking CO 2 incubators for flask culture. We have a Roche CEDEX HT bioanalyser, COBAS Upstream processing activities cover both mammalian and microbial cells as detailed in the respective sections. Microbial capabilities are based on the use of a variety of microbial systems for the production of recombinant proteins (soluble and insoluble).

6 Downstream Processing Our downstream capabilities are focused around the development and optimisation of manufacturing ready processes for a variety of product types. Examples of products encountered include recombinant therapeutic proteins, attenuated viruses (eg AAV), PEGylated proteins and complex biological nanopharmaceuticals. For microbial processes, purification can be optimised for both soluble products and those refolded from inclusion bodies. Our flexible facilities are appropriately equipped to allow for both lab and pilot scale purification. We have high throughput screening capabilities based on the use of automated liquid handling work stations. We have developed methods for rapid experimental design that integrate with automated methods for high throughput investigation and development of downstream unit operations such as protein refolding, precipitation and chromatographic purification. Integration with high throughput process development analytics, such as the LabChip GXII, enables rapid analysis of product quality and yield. By using lab scale equipment such as tangential flow filtration (TFF) and traditional or continuous chromatography systems, unit operations can be scaled for further optimisation or exploration of design space. Systems can be used as standalone operations or integrated, with options for gravimetric quantification, temperature regulation and highly efficient mixing, to allow for semi-automated processing and analysis. We also have industry standard capabilities for semi-automated and fully automated pilot scale process demonstration including separations, normal flow filtration, depth filtration, microfiltration, tangential flow filtration and chromatography unit operations. Our singleuse capabilities allow for disposable processing, including temperature regulated mixing systems and flexible filtration. Downstream processing service offerings include: Development of robust and scalable processes including the following unit operations: Primary separation/recovery steps (eg cell broth clarification, cell disruption, inclusion body recovery, protein folding, precipitation, depth filtration) Filtration normal flow (NFF) and tangential flow (TFF) Chromatography (batch and continuous) Conjugation or protein modification (eg PEGylation) Unit operation or full process scale up for demonstration at laboratory or pilot scale

7 Analytical Analytical science underpins almost all aspects of biopharmaceutical development and manufacture and we ensure the latest developments in analytical science are translated into our customer s projects. Our extensive analytical suite supports investigation and optimisation of the various stages of biopharmaceutical development and manufacture, helping to optimise product yield and quality. We provide comprehensive characterisation of product quality attributes such as glycan profile, levels of aggregation, secondary structure and charge variant profile as well as high throughput screening of product purity, titre and impurity clearance throughout downstream processing. We have Ion Torrent next generation sequencing capabilities to allow a genomics based approach to biopharmaceutical process optimisation, helping to identify important cellular features related to the performance of cell lines. CPI is also equipped with a Waters Synapt G2Si mass spectrometer to allow peptide mapping and comprehensive characterisation of post translational modifications, plus hydrogen deuterium exchange for higher order structure studies. In addition to applying our state of-the-art analytical tools to research and development projects, we also perform routine bioanalysis (cell count/viability, nutrients, metabolites, product titre, and product characterisation); stability testing; characterisation of reference standards; comparability testing (purity, potency and identity); method development, verification and transfer. Analytical testing and development services include: Purity and identity measurements Impurity measurements Potency and higher order structure Formulation and stability studies including comprehensive characterisation of aggregation Development of process specific analytical methods Process analytical technologies Product characterisation Molecular characterisation Method development Method transfer and verification

8 Fill and Finish Our Fill and Finish capabilities are focused on improving the sterile filling, finish and lyophilisation of biologic drugs....the future inspired. Fill and finish service offerings include: Handling a wide range of products (eg proteins, vaccines, DNA and viral vector solutions, viscous biopolymers and other nanoparticles) Filling volume ranging from ml Filling of up to 120 vials per hour Flexible bulk volume up to 20L Batch Lyophilisation covering: development of lyophilisation cycles in vials, flasks and bulk volumes; development and optimisation of multi-step lyophilisation cycles

9 To find out more about our full range of services visit: call: +44 (0) Industrial Biotechnology and Biorefining Printable Electronics Formulation Biologics Centre for Process Innovation Wilton Centre, Wilton, Redcar, Cleveland, TS10 4RF, United Kingdom T: +44 (0) E: W: Copyright Centre for Process Innovation Limited. All rights reserved.

Industrial Biotechnology and Biorefining

Industrial Biotechnology and Biorefining Industrial Biotechnology and Biorefining Industrial Biotechnology and Biorefining The Centre for Process Innovation From innovation to commercialisation The High Value Manufacturing Catapult is a partnership

More information

Healthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation

Healthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation Healthcare Healthcare The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation (CPI)

More information

Summer Training Program In Industrial Biotechnology BiOZEEN, Bangalore

Summer Training Program In Industrial Biotechnology BiOZEEN, Bangalore Summer Training Program In Industrial Biotechnology BiOZEEN, Bangalore BiOZEEN Summer Training Program in Industrial Microbiology & Fermentation Technology One small step can brighten your future Microbes

More information

Manufacturing Integrated Biologics Manufacturing

Manufacturing Integrated Biologics Manufacturing Manufacturing Integrated Biologics Manufacturing Integrated Biologics Manufacturing Abzena provides customer focused process development and manufacturing services for cgmp and non-gmp production of recombinant

More information

Development from Bench to Clinic

Development from Bench to Clinic Accelerating Novel Vaccine Development from Bench to Clinic Roger Lias. Ph.D. President Eden Biodesign, Inc Questions Questions are encouraged and can be asked by sending an email to: edenbiodesign@propelmg.com

More information

LFB BIOMANUFACTURING YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING

LFB BIOMANUFACTURING YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING COMMITMENT AND FLEXIBILITY LFB BIOMANUFACTURING is a medium-sized CDMO offering Bioproduction services, from an industrial facility

More information

INTEGRATED PRODUCTION PLATFORMS

INTEGRATED PRODUCTION PLATFORMS FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME PROCESS DEVELOPMENT, SCALE UP, GMP-COMPLIANT PRODUCTION AND CONSULTING INTEGRATED PRODUCTION PLATFORMS EVERYTHING STARTS WITH YOUR BRILLIANT

More information

Food and Drink. Food and Drink. The Centre for Process Innovation. From innovation to commercialisation

Food and Drink. Food and Drink. The Centre for Process Innovation. From innovation to commercialisation Food and Drink Food and Drink The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation

More information

Implementation of a Micro Bioreactor System for Platform Cell Culture Process Development at Cobra Biologics

Implementation of a Micro Bioreactor System for Platform Cell Culture Process Development at Cobra Biologics Implementation of a Micro Bioreactor System for Platform Cell Culture Process Development at Cobra Biologics Kristina Lae, Scientist, Cell Culture Cobra Biologics, Södertälje, Sweden Cobra Biologics and

More information

Biotechpharma company profile. Romanas Ramanauskas Business development manager

Biotechpharma company profile. Romanas Ramanauskas Business development manager Biotechpharma company profile Romanas Ramanauskas Business manager October, 2012 1 Contents History Company overview Services and capabilities Expression system and process Technology scale-up and GMP

More information

Advanced Microbial Protein Expression

Advanced Microbial Protein Expression Advanced Microbial Protein Expression Partners for Life Advancing tomorrow s medicines w A Biologics and Vaccines CDMO partner for your complete clinical journey Good science, experience and a quality

More information

The Elite Provider. Cell & Gene. Therapy Manufacturing

The Elite Provider. Cell & Gene. Therapy Manufacturing The Elite Provider Cell & Gene Therapy Manufacturing GMP Manufacturing Services The cgmp manufacturing in Vigene is compliant with US FDA and EU EMA regulatory requirements. The manufacturing area consists

More information

Overview Rentschler Biotechnologie

Overview Rentschler Biotechnologie Overview Rentschler Biotechnologie AusBiotech, Adelaide, 18.10.2011 Klaus B. Schoepe, PhD, SVP Client Relations - 1 - Our Mission As an independent leading, internationally operating service company, we

More information

Viral vectors Overcoming process. Dave Simpson PhD Process Development Manager

Viral vectors Overcoming process. Dave Simpson PhD Process Development Manager Viral vectors Overcoming process challenges to meet the clinical demands Dave Simpson PhD Process Development Manager Eden Biodesign Ltd Questions Questions are encouraged throughout the presentation and

More information

Challenges in Scaling Up Newly Developed Microbial Manufacturing Processes

Challenges in Scaling Up Newly Developed Microbial Manufacturing Processes Challenges in Scaling Up Newly Developed Microbial Manufacturing Processes Susan Dana Jones, Ph.D. BioProcess Technology Consultants BIO Process Zone Theater June 19, 2008 Microbial Process Development

More information

Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission

Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission 1 2 3 25 April 2014 EMA/CHMP/BWP/187338/2014 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on process validation for the manufacture of biotechnology-derived active substances

More information

Development. - Be Your Partner-

Development. - Be Your Partner- Development - Be Your Partner- 1 Product development and management 2 Product development and management A good product development is based on a strong product management. Mycenax sproject management

More information

Process Removal of Impurities in Biotech Products

Process Removal of Impurities in Biotech Products Process Removal of Impurities in Biotech Products CASSS Midwest Regional Forum October 5, 2017 Warren R. Emery Sr. Research Scientist Bioproduct R&D, Eli Lilly and Company Pharmaceutical Process Development

More information

Mammalian Expression Platform

Mammalian Expression Platform Mammalian Expression Platform Partners for Life Advancing tomorrow s medicines w Your CDMO partner for biologics and advanced therapies Good science, experience and a quality driven approach Line/Strain

More information

Executive summary A guide to setting up a National Technology and Innovation Centre

Executive summary A guide to setting up a National Technology and Innovation Centre How to Guide 1 First Edition Executive summary A guide to setting up a National Technology and Innovation Centre The Centre for Process Innovation From innovation to commercialisation Executive Summary

More information

GMP offer for lentiviral vectors.

GMP offer for lentiviral vectors. GMP offer for lentiviral vectors 1 Lentiviral vector manufacturing expert since 2005 More than 6000 premium integrative and non-integrative lentiviral vector R&D batches delivered since 2005 Cutting-edge

More information

Emerging and Enabling Technologies in Membrane Separations

Emerging and Enabling Technologies in Membrane Separations Emerging and Enabling Technologies in Membrane Separations Andrew L. Zydney Distinguished Professor of Chemical Engineering The Pennsylvania State University 2 nd International Symposium on Continuous

More information

PRAXIS. A publication by Bioengineering AG

PRAXIS. A publication by Bioengineering AG PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.

More information

Viral Products Expertise, Experience and Capability

Viral Products Expertise, Experience and Capability Viral Products Expertise, Experience and Capability Partners for Life Advancing tomorrow s medicines w Dedicated viral products facilities Your CDMO partner for biologics and advanced therapies Our state-of-the-art

More information

Debendra K. Sahoo INSTITUTE OF MICROBIAL TECHNOLOGY CHANDIGARH

Debendra K. Sahoo INSTITUTE OF MICROBIAL TECHNOLOGY CHANDIGARH Thursday 5 November EU-India PARTNERING EVENT Theme: Life sciences, biotechnology and biochemistry for sustainable non-food products and processes IMTECH Debendra K. Sahoo INSTITUTE OF MICROBIAL TECHNOLOGY

More information

IMPORTANCE OF CELL CULTURE MEDIA TO THE BIOPHARMACEUTICAL INDUSTRY

IMPORTANCE OF CELL CULTURE MEDIA TO THE BIOPHARMACEUTICAL INDUSTRY IMPORTANCE OF CELL CULTURE MEDIA TO THE BIOPHARMACEUTICAL INDUSTRY Research, development and production of biopharmaceuticals is growing rapidly, thanks to the increase of novel therapeutics and biosimilar

More information

Recent Developments & Future Directions in the Production of Monoclonal Antibodies. Rob Noel Plasma Product Biotechnology Conference 2009, Menorca

Recent Developments & Future Directions in the Production of Monoclonal Antibodies. Rob Noel Plasma Product Biotechnology Conference 2009, Menorca Recent Developments & Future Directions in the Production of Monoclonal Antibodies Rob Noel Plasma Product Biotechnology Conference 2009, Menorca Forecast sales by molecule type ($m), 2006 12 600,000 Pharmaceuticals

More information

FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS

FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS Close-up of large scale UF/DF control unit conditions and

More information

Calendar. The Clear Solution to Reach the Global Biopharma Audience. INTERNATIONAL

Calendar. The Clear Solution to Reach the Global Biopharma Audience.   INTERNATIONAL The Clear Solution to Reach the Global Biopharma Audience yvdavyd/getty Images & blackred/e+/getty Images 2017 EDITOrial Calendar Editorial Coverage Special Themed Issues January Biopharma Outlook for

More information

Subject Index. chromatography step, 125-

Subject Index. chromatography step, 125- A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade

More information

Kupers Luc IMI webinar

Kupers Luc IMI webinar Biomanufacturing 2020 (biomfg2020): Development of Innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes Kupers

More information

Subject Index. See for options on how to legitimately share published articles.

Subject Index. See   for options on how to legitimately share published articles. Downloaded via 148.251.232.83 on March 27, 2019 at 03:59:27 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. A Alert limits, description, 70

More information

Efficient Project Management of Outsourced Biopharmaceutical Development and Manufacturing Programs

Efficient Project Management of Outsourced Biopharmaceutical Development and Manufacturing Programs Efficient Project Management of Outsourced Biopharmaceutical Development and Manufacturing Programs Thomas C. Ransohoff and Howard L. Levine, Ph.D. BioProcess Technology Consultants Inc. Presented at IBC

More information

CASSS CMC Strategy Forum Barcelona, Spain. EBE Satellite Session Comparability Concept Paper 21 st March 2011

CASSS CMC Strategy Forum Barcelona, Spain. EBE Satellite Session Comparability Concept Paper 21 st March 2011 CASSS CMC Strategy Forum Barcelona, Spain EBE Satellite Session Comparability Concept Paper 21 st March 2011 Aim of concept paper Points to consider in planning and undertaking of comparability exercise

More information

The Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics

The Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics The Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics Visit of Alabama Biotech Oct 2014 Alain BERNARD Vice President GPS, UCB Technical Operations Tech Ops BioTech

More information

Detection and Quantitation of Residual Host Cell DNA

Detection and Quantitation of Residual Host Cell DNA Detection and Quantitation of Residual Host Cell DNA White Paper Author: Phil Kuhlman, Biopharmaceutical Technical Specialist 1 Abstract All biological drug products are required to be characterised for

More information

Continuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities

Continuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities Continuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities Erik Fouts, Ph.D. VP and Site Head, Novato Operations 3-4 December ASTM E2968 14 Continuous

More information

AAV vectors for gene therapy. Any Gene to Any Cell

AAV vectors for gene therapy. Any Gene to Any Cell AAV vectors for gene therapy Any Gene to Any Cell % Population WHY WORK WITH SIRION? OVERCOME MAJOR ROAD BLOCKS IN AAV GENE THERAPY Invent improved AAV vectors with optimized transduction and expression

More information

Scale up/scale down strategies and devices 16/11/2016

Scale up/scale down strategies and devices 16/11/2016 Scale up/scale down strategies and devices 16/11/2016 Valentina Mangiafridda MEng Gas Lab and Fermentation Manager 2016 Centre for Process Innovation Limited. All Rights Reserved. CPI mission We use applied

More information

BIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS

BIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS BIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS Supported By: Organised By: PROGRAMME OVERVIEW BIOLOGICS MAKE UP MORE THAN 1,000 MEDICINES AND VACCINES THAT TARGET MORE THAN 100 DISEASES. Unlike medicines

More information

ABL Europe s GMP manufacturing facility for viral vector production

ABL Europe s GMP manufacturing facility for viral vector production ABL Europe s GMP manufacturing facility for viral vector production New Production Capacity for Viral Vectors Success Story ABL Europe GMP manufacturing of viral vectors from non-adherent cell cultures

More information

Training Program 2019

Training Program 2019 www.bcc.ch info@bcc.ch Biofactory Competence Center SA Passage du Cardinal 13b 1700 Fribourg (CH) Training Program 2019 Training is delivered by subject matter experts from both academia and those with

More information

Preparative Protein Chemistry

Preparative Protein Chemistry Biochemistry 412 Preparative Protein Chemistry 19 February 2008 The Three Eras of Protein Purification 1. The Classical (Pre-Recombinant DNA) Era (pre-1978) - Proteins purified from natural sources only

More information

European Medicines Agency Evaluation of Medicines for Human Use

European Medicines Agency Evaluation of Medicines for Human Use European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL

More information

New proposal from the EC:

New proposal from the EC: New proposal from the EC: Gene therapy medicinal product means a biological medicinal product which has the following characteristics: a. it contains an active substance which contains or consists of a

More information

2009 INVESTOR DAY. BioPharmaceuticals. Ken Frank President BioPharmaceuticals December 17, Sustainable, Profitable Growth

2009 INVESTOR DAY. BioPharmaceuticals. Ken Frank President BioPharmaceuticals December 17, Sustainable, Profitable Growth 2009 INVESTOR DAY BioPharmaceuticals Ken Frank President BioPharmaceuticals December 17, 2009 Sustainable, Profitable Growth Life Sciences FY 2009 Total Sales $2,329.2 (amounts shown in millions) BioPharmaceuticals

More information

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities) May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological

More information

Course Agenda. Day One

Course Agenda. Day One Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an

More information

Guide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia

Guide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia Guide for the elaboration of monographs on synthetic peptides and recombinant DNA proteins European Pharmacopoeia European Directorate for the Quality of Medicines & HealthCare Edition Council of Europe,

More information

Purification Strategy for Antibodies in partnership with Mannheim University of Applied Sciences

Purification Strategy for Antibodies in partnership with Mannheim University of Applied Sciences Chromatography Purification Strategy for Antibodies in partnership with Mannheim University of Applied Sciences Putting theory into practice In today s evolving workplace, it is vital to understand why

More information

NEWSFLASH 03. FASILIS update. FASILIS: Stimulating new business development in Human Health

NEWSFLASH 03. FASILIS update. FASILIS: Stimulating new business development in Human Health NEWSFLASH 03 FASILIS: Stimulating new business development in Human Health FASILIS (Facility Sharing in Life Sciences) is an international pilot project creating transnational links between SMEs and a

More information

cgmp Cell & Gene Therapy

cgmp Cell & Gene Therapy Updated Edition cgmp Cell & Gene Therapy AAV, Adenovirus, and Lentivirus PD and Production Handbook Vigene - the cgmp Viral Vector Experts Table of Contents Vigene cgmp overview... 3 Vigene manufacturing

More information

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation

More information

Future Perspectives of Antibody Manufacturing

Future Perspectives of Antibody Manufacturing BioProduction 2005 Amsterdam Future Perspectives of Antibody Manufacturing John Birch Lonza Biologics Monoclonal Antibodies A Success Story Fastest growing segment of the pharmaceutical market Sales forecast

More information

Thermo Scientific Metabolic Pathway Design Process Cell culture media and process optimization approaches for optimal biotherapeutic production

Thermo Scientific Metabolic Pathway Design Process Cell culture media and process optimization approaches for optimal biotherapeutic production Thermo Scientific Metabolic Pathway Design Process Cell culture media and process optimization approaches for optimal biotherapeutic production May/June 2013 1 The world leader in serving science Agenda

More information

INSIDE THE CSIR BIOMANUFACTURING INDUSTRY DEVELOPMENT CENTRE - BIDC

INSIDE THE CSIR BIOMANUFACTURING INDUSTRY DEVELOPMENT CENTRE - BIDC INSIDE THE CSIR BIOMANUFACTURING INDUSTRY DEVELOPMENT CENTRE - BIDC OVERVIEW The CSIR Biomanufacturing Industry Development Centre (BIDC) is a world-class facility established to translate biotechnology-based

More information

The Innovate UK response to the Innovative Medicines Initiative consultation Facilitating the translation of advanced therapies to patients in Europe

The Innovate UK response to the Innovative Medicines Initiative consultation Facilitating the translation of advanced therapies to patients in Europe The Innovate UK response to the Innovative Medicines Initiative consultation Facilitating the translation of advanced therapies to patients in Europe Innovate UK and ATMP background 1. Innovate UK is the

More information

Critical Quality Attributes for Live Viral Vaccines. Mark S. Galinski Vaccine Analytical Sciences, MedImmune, Mountain View, CA USA

Critical Quality Attributes for Live Viral Vaccines. Mark S. Galinski Vaccine Analytical Sciences, MedImmune, Mountain View, CA USA Critical Quality Attributes for Live Viral Vaccines Mark S. Galinski Vaccine Analytical Sciences, MedImmune, Mountain View, CA USA Terminology Quality Release Standards The specifications and procedures

More information

Continuously Improving Bioprocesses: Biopharmaceutical Capabilities

Continuously Improving Bioprocesses: Biopharmaceutical Capabilities Continuously Improving Bioprocesses: Biopharmaceutical Capabilities Pall Corporation A Legacy of Innovation Dr. David B. Pall Founded by Dr. David B. Pall in 1946, Pall Corporation has grown from a company

More information

Downstream Processing for Production of Biologicals

Downstream Processing for Production of Biologicals Downstream Processing for Production of Biologicals... Overview: Bio-therapeutics form an important part of modern medicines. Complexity of bio-therapeutics molecules necessitates elaborate purification

More information

Sartorius Stedim Cellca. Custom Cell Line & Process Development for Pharmaceutical Purposes

Sartorius Stedim Cellca. Custom Cell Line & Process Development for Pharmaceutical Purposes Sartorius Stedim Cellca Custom Cell Line & Process Development for Pharmaceutical Purposes May 2017 Overview of Contents 1 2 3 Cellca History Overview: Cellca Technology Platform Products & Services 4

More information

Specialty Lab Services. Deep science at scale

Specialty Lab Services. Deep science at scale Specialty Lab Services Deep science at scale Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical

More information

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

Regulatory Issues and Drug Product Approval for Biopharmaceuticals Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop

More information

THE ANALYTICAL TOOLBOX FOR VIRAL VECTOR CHARACTERISATION: PROGRESS AND CHALLENGES

THE ANALYTICAL TOOLBOX FOR VIRAL VECTOR CHARACTERISATION: PROGRESS AND CHALLENGES AMC Technical Meeting 4 th October 2018 THE ANALYTICAL TOOLBOX FOR VIRAL VECTOR CHARACTERISATION: PROGRESS AND CHALLENGES Dr Helen Young and Dr Natasha Lethbridge Upstream Scientist and Project Manager

More information

APPROACHES TO IMPROVING THE PERFORMANCE OF MAMMALIAN CELL CULTURES FOR PROTEIN PRODUCTION

APPROACHES TO IMPROVING THE PERFORMANCE OF MAMMALIAN CELL CULTURES FOR PROTEIN PRODUCTION BioLOGIC USA BOSTON, 20 th OCTOBER 2004 APPROACHES TO IMPROVING THE PERFORMANCE OF MAMMALIAN CELL CULTURES FOR PROTEIN PRODUCTION Dr Robert Gay Lonza Biologics 2004 The Challenge of the MAb Market Global

More information

Guideline for the quality, safety and efficacy of follow-on biological medicinal products

Guideline for the quality, safety and efficacy of follow-on biological medicinal products Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a

More information

Comparability Is Not a Nightmare, Just Think Ahead!

Comparability Is Not a Nightmare, Just Think Ahead! Comparability Is Not a Nightmare, Just Think Ahead! Margarida Menezes Ferreira Senior Assessor at INFARMED PT expert at BWP/CHMP - EMA member of the CAT - EMA (margarida.menezes@infarmed.pt) I attend this

More information

PATfix TM. Lead the way of your process

PATfix TM.  Lead the way of your process PATfix TM Lead the way of your process P A T f i x S O F T W A R E Short description incyght Chromatography Data Science Software Production of high value biological therapeutics usually involves complex

More information

About Us. What We Do and Who We Are. Company. Management

About Us. What We Do and Who We Are. Company. Management About Us What We Do and Who We Are Company Management ProJect Pharmaceutics transforms all kinds of chemical and biological ingredients into pioneering drugs. We are experts in formulation science and

More information

Gala s Gene Product Expression (GPEx ) Platform

Gala s Gene Product Expression (GPEx ) Platform Gala Biotech A Company with Gene Insertion and Manufacturing Technologies for the Next Generation of Gene Expression and Biologics Production Gala s Gene Product Expression (GPEx ) Platform Rapid creation

More information

CREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO

CREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO CREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO STATE-OF-THE-ART GMP FACILITIES Our sites in Jena and Halle (Germany) provide a complete range

More information

Bioprocessing Challenges: High-Titer Mammalian-Based Cell Systems. Elements influencing the way Biologics may be manufactured /supplied in the future

Bioprocessing Challenges: High-Titer Mammalian-Based Cell Systems. Elements influencing the way Biologics may be manufactured /supplied in the future Bioprocessing Challenges: High-Titer Mammalian-Based Cell Systems Jonathan Romero CMC Leadership, Technical Development Pharmaceutical Operations & Technology 2015 ISPE PRODUCT SHOW Business Drivers Elements

More information

Cellca Technology Platform

Cellca Technology Platform Cellca Technology Platform Custom Cell Line & Process Development April 2018 Overview: Cellca Technology Platform Cellca CMO/Client Cell Line Development Process Development Process Transfer GMP Production

More information

Welcome Biotech 101. Outline. Before the Floor. Manufacturing Process. Supporting Cast 4/22/2013

Welcome Biotech 101. Outline. Before the Floor. Manufacturing Process. Supporting Cast 4/22/2013 Welcome Biotech 101 Outline Before the Floor All the activities that happen before large scale cgmp manufacturing Manufacturing Process Manufacturing steps Equipment Requirements How it all works together

More information

Viral Clearance Studies

Viral Clearance Studies Viral Clearance Studies viral clearance studies from the industry leader with unmatched experience and expertise Viral clearance is a critical component of regulatory submissions as it helps demonstrate

More information

Fujifilm Diosynth Biotechnologies Texas

Fujifilm Diosynth Biotechnologies Texas Fujifilm Diosynth Biotechnologies Texas Contract Development and Manufacturing Organization Partners for Life Advancing tomorrow s medicines. Global Vision To be the leading and most trusted global Contract

More information

Effectively utilizing Post Translational Modification analysis to fast track process development for Biosimilars

Effectively utilizing Post Translational Modification analysis to fast track process development for Biosimilars Effectively utilizing Post Translational Modification analysis to fast track process development for Biosimilars Sanjeev Gupta DGM-Advanced Biotech (R&D) Ipca Laboratories Ltd., Mumbai, India March 04,

More information

Fast Trak Services: Long-term collaboration supports speed to market in single-use biomanufacturing

Fast Trak Services: Long-term collaboration supports speed to market in single-use biomanufacturing GE Healthcare Fast Trak Services: Long-term collaboration supports speed to market in single-use biomanufacturing A case study Fast Trak Services Long-term collaboration supports speed to market in single-use

More information

CHO-GSN PLATFORM STABLE CELL LINE GENERATION. NR v5

CHO-GSN PLATFORM STABLE CELL LINE GENERATION. NR v5 CHO-GSN PLATFORM STABLE CELL LINE GENERATION NR3160 20180122 v5 Highlights of LakePharma s CHO-GSN Cell Line Platform 2 LakePharma proprietary technology Complete cell line lineage and clear path to commercialization,

More information

EMA Workshop on the therapeutic use of bacteriophages. London, June 8 th 2015 Laurent Bretaudeau, R&D Director

EMA Workshop on the therapeutic use of bacteriophages. London, June 8 th 2015 Laurent Bretaudeau, R&D Director EMA Workshop on the therapeutic use of bacteriophages London, June 8 th 2015 Laurent Bretaudeau, R&D Director Presentation outlines Foreword : Company overview / phage therapy field, Strategy for the management

More information

Fast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China

Fast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China GE Healthcare Fast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China A case study Fast Trak Services Ongoing collaboration aims to accelerate biosimilar approval in China

More information

SCIENTIFIC. Process for Success. CHO ONE Media System. Expression Media for Fed-Batch Culture

SCIENTIFIC. Process for Success. CHO ONE Media System. Expression Media for Fed-Batch Culture CAPRICORN SCIENTIFIC Process for Success CHO ONE Media System Expression Media for Fed-Batch Culture Culture for Life www.capricorn-scientific.com 2 Capricorn Scientific as a young established cell culture

More information

Essential Product and Process Parameters in Summary

Essential Product and Process Parameters in Summary CHAPTER 3 Essential Product and Process Parameters in Summary 3.1 General Considerations During the process development stage, a number of variables need to be considered; they include formulation details,

More information

BIOTECHNOLOGY. Course Syllabus. Section A: Engineering Mathematics. Subject Code: BT. Course Structure. Engineering Mathematics. General Biotechnology

BIOTECHNOLOGY. Course Syllabus. Section A: Engineering Mathematics. Subject Code: BT. Course Structure. Engineering Mathematics. General Biotechnology BIOTECHNOLOGY Subject Code: BT Course Structure Sections/Units Section A Section B Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Unit 7 Section C Section D Section E Topics Engineering Mathematics General

More information

Thermo Scientific Nucleic Acid Technologies

Thermo Scientific Nucleic Acid Technologies Thermo Scientific Nucleic Acid Technologies Phosphoramidites for Oligonucleotide Synthesis High Purity Nucleotides and Polynucleotides Fluorescent Labeling and Detection Custom Chemistries Molecular Biology

More information

Manufacturing Viral Gene Therapy Vectors: General Approaches and Challenges John T. Gray

Manufacturing Viral Gene Therapy Vectors: General Approaches and Challenges John T. Gray Manufacturing Viral Gene Therapy s: 1 Dr. Vice President, Research & Development Audentes Therapeutics, Inc. San Francisco, USA Natural virus life cycle Late Early Viral Virally infected cell Naïve cell

More information

Virus Filtration for Biosimilars : From needs to Solutions

Virus Filtration for Biosimilars : From needs to Solutions Virus Filtration for Biosimilars : From needs to Solutions 3 rd International Conference and Exhibition on Biowaivers, Biologics and Biosimilars - Hyderabad Tathagata Ray Layout of Presentation 1 Virus

More information

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from

More information

MagSi Beads. Magnetic Silica Beads for Life Science and Biotechnology study

MagSi Beads. Magnetic Silica Beads for Life Science and Biotechnology study MagSi Beads Magnetic Silica Beads for Life Science and Biotechnology study MagnaMedics Diagnostics B.V. / Rev. 9.2 / 2012 Wide range of products for numerous applications MagnaMedics separation solutions

More information

Modern Approaches to Process Understanding

Modern Approaches to Process Understanding Biomanufacturing and Process Development (BPD) Modern Approaches to Process Understanding Thursday, September 18, 2014 1:00 pm - Registration begins 1:15 5:00 pm - Presentations & Networking North Carolina

More information

Custom Antibodies & Recombinant Proteins

Custom Antibodies & Recombinant Proteins Custom Antibodies & Recombinant Proteins INTRODUCTION Custom services to meet your research and development requirements Improvements in health, medicine and diagnostics over the past century can be largely

More information

Current Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues

Current Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues Current Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues Dr. René Thürmer BfArM - and dmedical ldevices AGAH Workshop on Liposomal Formulations Bonn / 21.

More information

J.T.Baker HPLE Sugars

J.T.Baker HPLE Sugars J.T.Baker HPLE Sugars J.T. Baker HPLE Sugars IMPROVE YIELDS Galactose Monosaccharide used in upstream processing as cell culture nutrient Improved purity increases performance and yields HIGH PURITY, LOW

More information

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials 1 2 3 23 June 2016 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the requirements for quality documentation concerning biological investigational

More information

Expression of Next Generation Biologics Requires Next Generation Expression Systems

Expression of Next Generation Biologics Requires Next Generation Expression Systems Expression of Next Generation Biologics Requires Next Generation Expression Systems Joachim Klein, Ph.D., Associate Director, Head of Strain Development and Cell Banking Georg Blaser, Ph.D., Associate

More information

Accelerate Your Process Development With High-Throughput, Single-Use, Fully Automated Bioreactors. White Paper. by Mwai Ngibuini

Accelerate Your Process Development With High-Throughput, Single-Use, Fully Automated Bioreactors. White Paper. by Mwai Ngibuini Accelerate Your Process Development With High-Throughput, Single-Use, Fully Automated Bioreactors White Paper by Mwai Ngibuini Contents 3 Introduction 4 Costly Failures and Slowdowns 4 Enter the ambr 250

More information

Lentiviral Vector Manufacturing Challenges and Solutions

Lentiviral Vector Manufacturing Challenges and Solutions Lentiviral Vector Manufacturing Challenges and Solutions Bo Kara Cell Gene Therapy CMC Elizabeth and Patience Save the Children clinic attendee Liberia Photo credit Martin Web/Save the Children Strategy:

More information

The Value of Batch Process Design in a Chemical Engineering Education

The Value of Batch Process Design in a Chemical Engineering Education The Value of Batch Process Design in a Chemical Engineering Education by Jack Vinson, PhD + Product Manager, Batch Process Development Aspen Technology Abstract: Process design for the batch industries,

More information

Application of Disposable Technologies in Biopharmaceutical Manufacturing

Application of Disposable Technologies in Biopharmaceutical Manufacturing BMD Summit, Disposables for Biopharm Production 13th December 2005 Reston, VA, USA Application of Disposable Technologies in Biopharmaceutical Manufacturing Martin Wrankmore, Continuous Improvement Lead,

More information